公开(公告)号：EP4371560A3

公开(公告)日：2024-08-21

申请号：EP24160306.7

申请日：2010-10-01

Applicant: Boehringer Ingelheim International GmbH

Inventor： SCHNEIDER, Peter ,  EISENREICH, Wolfram ,  PEARNCHOB, Nantharat

IPC: A61K31/155 ,  A61K9/20 ,  A61K45/06 ,  A61K31/35

CPC classification number: A61K9/2009 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2072 ,  A61K9/209 ,  A61K9/2866 ,  A61K31/155 ,  A61K31/351 ,  A61K45/06 ,  A61P1/16 ,  A61P13/12 ,  A61P25/00 ,  A61P27/12 ,  A61P3/00 ,  A61P3/04 ,  A61P3/06 ,  A61P3/08 ,  A61P43/00 ,  A61P5/48 ,  A61P5/50 ,  A61P9/00 ,  A61P9/10 ,  A61P3/10 ,  A61K31/35

Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a SGLT-2 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

公开(公告)号：EP3404118A1

公开(公告)日：2018-11-21

申请号：EP18172585.4

申请日：2018-05-16

Applicant: Oncology Venture ApS

Inventor： KNUDSEN, Steen

IPC: C12Q1/6886

CPC classification number: C12Q1/6886 ,  A61K31/351 ,  A61K45/06 ,  A61P35/02 ,  C12Q2600/106 ,  C12Q2600/158 ,  G16H20/10 ,  G16H50/20 ,  G16H50/30

Abstract: The present invention features methods, devices, and kits for detecting a level of one or more biomarkers in a patient with cancer or determining the responsiveness of a patient with cancer to a treatment, such as treatment with an anthracycline. The invention further includes methods of treating a patient with cancer by administering, e.g., the anthracycline.

公开(公告)号：EP2952206B1

公开(公告)日：2018-10-24

申请号：EP14746685.8

申请日：2014-02-03

Applicant: Taisho Pharmaceutical Co., Ltd.

Inventor： YAMAMOTO, Daisuke ,  IO, Fusayo ,  YAMAMOTO, Koji

IPC: A61K45/00 ,  A61K31/351 ,  A61P1/10 ,  A61P43/00 ,  C07D309/10 ,  A61K9/16 ,  A61K9/20 ,  A61K31/7034

CPC classification number: A61K31/7034 ,  A61K9/1652 ,  A61K9/2059 ,  A61K31/351 ,  C07D309/10

Abstract: New drugs useful in the prevention or treatment of constipation are provided, in which SGLT1 inhibiting compounds, in particular, a 4-isopropylphenyl glucitol compound represented by the following formula (I), or pharmaceutically acceptable salts thereof are contained as an active ingredient:

公开(公告)号：EP3368031A1

公开(公告)日：2018-09-05

申请号：EP16788558.1

申请日：2016-10-20

Applicant: Helperby Therapeutics Limited

Inventor： COATES, Anthony ,  HU, Yanmin

IPC: A61K31/351 ,  A61K31/736 ,  A61P31/00 ,  A61K31/4745 ,  A61K31/7036

CPC classification number: A61K31/4745 ,  A61K9/0014 ,  A61K9/0053 ,  A61K9/0073 ,  A61K31/351 ,  A61K31/7036 ,  A61K2300/00 ,  A61P31/06 ,  A61P31/08 ,  Y02A50/401 ,  Y02A50/404 ,  Y02A50/406 ,  Y02A50/469 ,  Y02A50/475 ,  Y02A50/479 ,  Y02A50/481 ,  Y02A50/483

Abstract: The invention provides a combination comprising 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable derivative thereof, mupirocin or a pharmaceutically acceptable derivative thereof and neomycin or a pharmaceutically acceptable derivative thereof. This triple combination is particularly useful for the treatment and/or prevention of microbial infections.

公开(公告)号：EP3355875A2

公开(公告)日：2018-08-08

申请号：EP16782161.0

申请日：2016-09-30

Applicant: Gilead Sciences, Inc. ,  ONO Pharmaceutical Co., Ltd.

Inventor： VENKATARAMAN, Sriram ,  TUMAS, Daniel ,  TANAKA, Kohei ,  YASUHIRO, Tomoko ,  YOSHIZAWA, Toshio

IPC: A61K31/122 ,  A61K31/351 ,  A61K31/4748 ,  A61K31/522 ,  A61K31/675 ,  A61P35/00

CPC classification number: A61K31/522 ,  A61K31/122 ,  A61K31/351 ,  A61K31/4748 ,  A61K31/675 ,  A61K2300/00

Abstract: Provided herein are methods relating to a therapeutic strategy for treatment of cancer, including hematological malignancies. In particular, the methods include administration of a Btk inhibitor and a checkpoint inhibitor, including combinations in which the Btk inhibitor is 6-amino-9-[(3R)-I-(2-butynoyl)-3- pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one, or a pharmaceutically acceptable salt thereof, and the checkpoint inhibitor is selected from inhibitors of PD-1, PD-L1, and CTLA-4.

公开(公告)号：EP3350158A1

公开(公告)日：2018-07-25

申请号：EP16847451.8

申请日：2016-09-16

Applicant: Metacrine, Inc.

Inventor： SMITH, Nicholas D. ,  GOVEK, Steven P. ,  NAGASAWA, Johnny Y.

IPC: C07C233/55 ,  C07C255/60 ,  C07C233/63 ,  C07D309/06 ,  C07D305/06 ,  A61K31/16

CPC classification number: C07C233/54 ,  A61K31/16 ,  A61K31/216 ,  A61K31/27 ,  A61K31/277 ,  A61K31/337 ,  A61K31/351 ,  A61K31/36 ,  A61K31/382 ,  A61K31/397 ,  A61K31/402 ,  A61K31/404 ,  A61K31/415 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/426 ,  A61K31/4406 ,  A61K31/4453 ,  A61K31/45 ,  A61K31/4965 ,  A61K31/50 ,  A61K31/505 ,  A61K31/5375 ,  A61K45/06 ,  A61P1/16 ,  C07C233/63 ,  C07C233/65 ,  C07C233/81 ,  C07C233/87 ,  C07C235/04 ,  C07C235/16 ,  C07C235/40 ,  C07C235/56 ,  C07C235/64 ,  C07C235/82 ,  C07C237/24 ,  C07C255/57 ,  C07C255/60 ,  C07C271/24 ,  C07C271/28 ,  C07C311/07 ,  C07C311/08 ,  C07C317/32 ,  C07C317/44 ,  C07C323/50 ,  C07C323/61 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/18 ,  C07C2602/16 ,  C07C2602/42 ,  C07C2603/74 ,  C07D205/04 ,  C07D209/04 ,  C07D211/06 ,  C07D211/62 ,  C07D211/76 ,  C07D211/94 ,  C07D211/96 ,  C07D213/40 ,  C07D231/12 ,  C07D231/56 ,  C07D235/04 ,  C07D235/08 ,  C07D237/20 ,  C07D239/42 ,  C07D241/20 ,  C07D249/18 ,  C07D261/08 ,  C07D265/30 ,  C07D277/28 ,  C07D295/088 ,  C07D295/135 ,  C07D295/195 ,  C07D295/26 ,  C07D305/08 ,  C07D309/08 ,  C07D317/58 ,  C07D319/12 ,  C07D335/02 ,  A61K2300/00

Abstract: Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

公开(公告)号：EP3256135A4

公开(公告)日：2018-06-27

申请号：EP16748836

申请日：2016-02-09

Applicant: YEDA RES & DEV

Inventor： SAGI IRIT ,  TALMI-FRANK DALIT ,  SOLOMONOV INNA ,  AMIT IDO

IPC: A61K31/65 ,  A61K31/196 ,  A61K31/215 ,  A61K31/351 ,  A61K38/39 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P31/16 ,  C07K16/40

CPC classification number: A61K39/3955 ,  A61K31/196 ,  A61K31/215 ,  A61K31/351 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/40 ,  A61K2300/00

Abstract: A method of treating or preventing a disease associated with a secondary infection in a subject infected with a pathogen is provided. The method comprises administering to the subject a therapeutically effective amount of an anti-pathogenic agent directed towards the pathogen and a therapeutically effective amount of an agent which down-regulates at least one extracellular matrix-associated polypeptide.

公开(公告)号：EP3319599A1

公开(公告)日：2018-05-16

申请号：EP16736866.1

申请日：2016-07-08

Applicant: Ceva Santé Animale

Inventor： VARLOUD, Marie ,  HODGKINS, Elizabeth

IPC: A61K31/216 ,  A61K31/34 ,  A61K31/4402 ,  A61K45/06 ,  A61P33/10 ,  A61P43/00 ,  A61K31/215 ,  A01N43/00

CPC classification number: A61K31/341 ,  A01N51/00 ,  A01N53/00 ,  A61K9/0017 ,  A61K31/215 ,  A61K31/216 ,  A61K31/34 ,  A61K31/351 ,  A61K31/4402 ,  A61K45/06 ,  A61K2300/00 ,  A61P33/10 ,  A01N43/40

Abstract: This invention relates to a method of controlling the spread of dirofilariosis, such as for example heartworm, by administering to at least one non-human animal infested with filarioid nematodes such as Dirofilaria spp or susceptible to have been infested with filarioid nematodes such as Dirofilaria spp, an effective dose of a combination of a neonicotinoid compound and a pyrethroid compound.

公开(公告)号：EP3224253A4

公开(公告)日：2018-05-09

申请号：EP15862932

申请日：2015-11-24

Applicant: ACTURUM REAL ESTATE AB

Inventor： SÖDERMAN PETER ,  SVENSSON MATS A ,  KERS ANNIKA ,  ÖHBERG LISELOTT ,  HÖGDIN KATHARINA ,  HETTMAN ANDREAS ,  HALLBERG JESPER ,  EK MARIA ,  BYLUND JOHAN ,  NORD JOHAN

IPC: C07D309/06 ,  A61K31/18 ,  A61K31/351 ,  A61P29/00 ,  C07C311/21

CPC classification number: C07D309/06 ,  A61K31/18 ,  A61K31/351 ,  A61K45/06 ,  C07C311/39 ,  C07C2601/14

Abstract: The present invention relates to bis(sulfonamide) compounds and pharmaceutically acceptable salts thereof. The present invention also relates to pharmaceutical compositions comprising these compounds and to their use as a medicament for the treatment and/or prevention of a disease, disorder or condition in which modulation of microsomal prostaglandin E synthase-1 activity is beneficial, such as pain, inflammation and cancer.

公开(公告)号：EP3300740A1

公开(公告)日：2018-04-04

申请号：EP17186931.6

申请日：2013-07-31

Applicant: Stealth Peptides International, Inc.

Inventor： WILSON, Travsi D. ,  BAMBERGER, Mark ,  BLAKEY, Brian

IPC: A61K38/07 ,  A61K45/06 ,  A61K31/215 ,  A61K31/22 ,  A61K31/351 ,  A61K31/366 ,  A61K31/40 ,  A61K31/404 ,  A61K31/505 ,  A61P9/10

CPC classification number: A61K38/07 ,  A61K31/215 ,  A61K31/22 ,  A61K31/351 ,  A61K31/366 ,  A61K31/40 ,  A61K31/404 ,  A61K31/505 ,  A61K45/06 ,  A61P9/10 ,  A61K2300/00

Abstract: Disclosed herein are methods and compositions for preventing or treating atherosclerosis in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and, in some applications, a second active agent, to subjects in need thereof.

Abstract translation: 本文公开了用于预防或治疗哺乳动物受试者动脉粥样硬化的方法和组合物。 该方法包括向受试者施用有效量的芳香族阳离子肽，并且在一些应用中，向有需要的受试者施用第二活性剂。